Centrex Limited (ASX:CXM) Reconvenes Second Meeting of Creditors
Centrex Limited (ASX:CXM) reconvenes its second creditors meeting, proposing a DOCA by PRL Global Limited.
Tag: Regulatory News & Compliance
Syntara Limited (ASX:SNT) Receives FDA Fast Track Designation for SNT-5505
Syntara Limited (ASX:SNT) secures FDA Fast Track for its myelofibrosis treatment SNT-5505, accelerating its development towards becoming a new standard of care.
Cazaly Resources (ASX:CAZ) Receives Approvals for Drilling at Goongarrie Gold Project
Cazaly Resources (ASX:CAZ) secures approval to begin drilling at Goongarrie Gold Project, advancing its exploration efforts.
Lithium Plus Minerals (ASX:LPM) Retracts Pricing Statements and Announces Beryllium Discoveries
Lithium Plus Minerals (ASX:LPM) retracts previous pricing information and announces new beryllium mineral discoveries at Arunta Projects.
Tivan Limited (ASX:TVN) Awarded Grants for Sandover Fluorite Project
Tivan Limited (ASX:TVN) secures $150,000 in grants for its Sandover Fluorite Project, advancing exploration in central Australia.
Dateline Resources Limited (ASX:DTR) Announces OTCQB Uplisting and Colosseum Project Developments
Dateline Resources (ASX:DTR) announces OTCQB uplisting and updates on the Colosseum Gold-REE Project, boosting US investor access.
Toys’R’Us ANZ Limited (ASX:TOY) Appoints Voluntary Administrators
Toys’R’Us ANZ (ASX:TOY) appoints voluntary administrators amid insolvency risks, suspending ASX trading.
Mayne Pharma Group Limited (ASX:MYX) Updates on Scheme of Arrangement with Cosette
Mayne Pharma (ASX:MYX) updates investors on its Scheme of Arrangement with Cosette, addressing recent regulatory and contractual developments.
Engenco Limited (ASX:EGN) Receives Increased Takeover Offer
Elph Investments increases its takeover offer for Engenco Limited (ASX:EGN) from $0.305 to $0.31 per share.
Noxopharm Limited (ASX:NOX) Receives Approval for HERACLES Clinical Trial
Noxopharm Limited (ASX:NOX) receives ethics approval for its innovative HERACLES clinical trial, advancing new treatments for chronic inflammatory diseases.